Device Trial Radar · NCT02385292
Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation
Last checked: Nov 20, 2026Latest source record: Oct 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
May 31, 2015
Primary completion
Mar 31, 2016
Study completion Mar 31, 2016
Sponsor
- Lead sponsor
- Oculeve, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 11, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are: * To compare the change in levels of tear proteins and inflammatory mediators pre and post administration between the intranasal and extranasal applications * To compare the goblet cell count following application between the intranasal and extranasal applications * To compare fluorescein tear clearance with the application of the device intranasally and extranasally applications
Conditions
- Dry Eye Syndromes
Interventions
Oculeve Intranasal Lacrimal NeurostimulatorDevice
The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fluorescein Tear Clearance With ApplicationTime frame: Day 1
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Grutzmacher, Lewis & Sierra
Sacramento, California
Baylor College of Medicine, Department of Ophthalmology
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.